Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 55Head & Neck 11Thoracic 3Other neoplasm 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1

Interventions

Rituximab 1401Cyclophosphamide 1305Vincristine 668Doxorubicin 587Etoposide 527Prednisone 510Cytarabine 486fludarabine 469Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 260ibrutinib 258obinutuzumab 235Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endoscopy × Lymphoid × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡